Health Industry Shifts: New Deals and Rising Trends

Thermo Fisher acquires drug trial software firm Clario for up to $9.4bn

In a major private equity buy-out deal, life science giant Thermo Fisher Scientific will pay up to $9.4bn cash to acquire drug trial data software company Clario. Read more: Thermo Fisher acquires drug trial software firm Clario for up to $9.4bn

Health Industry Shifts: New Deals and Rising Trends

Health Industry Shifts: New Deals and Rising Trends The health industry is witnessing significant developments, with Thermo Fisher leading the charge by purchasing Clario, a clinical services provider, for up to $9.4 billion. This acquisition aims to reinforce Thermo Fisher's position in clinical trial research, particularly as demand recovers in the United States.Centene Corporation has seen a surprising quarterly profit, prompting a rise in it…

Thermo Fisher to Buy Clinical Services Provider ClarioThermo Fisher to ...

Thermo Fisher to buy data solutions-focused Clario for up to $9.4B

Thermo Fisher announced Wednesday that it will pay $8.9 billion in cash to acquire the data solutions company Clario. In addition to the upfront payment, Thermo has agreed to shell out $125 million in January ...

Thermo Fisher to Acquire Clario in $8.9B Cash Deal

In a move set to reshape the landscape of clinical research technology, Thermo Fisher Scientific Inc. announced Wednesday that it will acquire Clario Holdings Inc. from a consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven for $8.875 billion in cash. The all-cash acquisition will deepen Thermo Fisher’s foothold in digital clinical trial solutions and expand its artificial intelligence-driven data capabilities. A Strategic Merger …